Analysts Issue Forecasts for Syros Pharmaceuticals, Inc.’s FY2028 Earnings (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Brookline Capital Management issued their FY2028 EPS estimates for shares of Syros Pharmaceuticals in a report released on Wednesday, March 27th. Brookline Capital Management analyst L. Cann forecasts that the company will earn $11.61 per share for the year. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Separately, StockNews.com downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

Syros Pharmaceuticals Stock Performance

Syros Pharmaceuticals stock opened at $5.84 on Thursday. The firm has a market capitalization of $123.05 million, a P/E ratio of -1.56 and a beta of 1.79. The company’s 50-day moving average is $6.89 and its 200 day moving average is $5.06. Syros Pharmaceuticals has a 1-year low of $2.09 and a 1-year high of $8.17. The company has a debt-to-equity ratio of 1.09, a current ratio of 4.31 and a quick ratio of 4.31.

Institutional Trading of Syros Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC purchased a new position in shares of Syros Pharmaceuticals during the 1st quarter worth approximately $29,000. Sawtooth Solutions LLC purchased a new position in Syros Pharmaceuticals during the 1st quarter worth $29,000. Prudential Financial Inc. purchased a new stake in shares of Syros Pharmaceuticals in the second quarter valued at about $32,000. BNP Paribas Arbitrage SA lifted its stake in shares of Syros Pharmaceuticals by 540.4% in the second quarter. BNP Paribas Arbitrage SA now owns 34,608 shares of the company’s stock valued at $33,000 after purchasing an additional 29,204 shares during the period. Finally, Two Sigma Investments LP raised its position in Syros Pharmaceuticals by 30.0% during the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company’s stock worth $36,000 after acquiring an additional 3,139 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.